NRSN vs. RPTX, PDSB, SPRO, OPTN, DYAI, XLO, TNXP, IVVD, ACHL, and ICCC
Should you be buying NeuroSense Therapeutics stock or one of its competitors? The main competitors of NeuroSense Therapeutics include Repare Therapeutics (RPTX), PDS Biotechnology (PDSB), Spero Therapeutics (SPRO), OptiNose (OPTN), Dyadic International (DYAI), Xilio Therapeutics (XLO), Tonix Pharmaceuticals (TNXP), Invivyd (IVVD), Achilles Therapeutics (ACHL), and ImmuCell (ICCC). These companies are all part of the "pharmaceutical products" industry.
NeuroSense Therapeutics vs.
NeuroSense Therapeutics (NASDAQ:NRSN) and Repare Therapeutics (NASDAQ:RPTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, community ranking, risk, media sentiment and profitability.
NeuroSense Therapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Comparatively, Repare Therapeutics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500.
NeuroSense Therapeutics has higher earnings, but lower revenue than Repare Therapeutics. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Repare Therapeutics, indicating that it is currently the more affordable of the two stocks.
NeuroSense Therapeutics has a net margin of 0.00% compared to Repare Therapeutics' net margin of -99.76%. NeuroSense Therapeutics' return on equity of 0.00% beat Repare Therapeutics' return on equity.
1.0% of NeuroSense Therapeutics shares are held by institutional investors. Comparatively, 85.1% of Repare Therapeutics shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by insiders. Comparatively, 21.6% of Repare Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Repare Therapeutics received 40 more outperform votes than NeuroSense Therapeutics when rated by MarketBeat users. However, 66.67% of users gave NeuroSense Therapeutics an outperform vote while only 63.64% of users gave Repare Therapeutics an outperform vote.
Repare Therapeutics has a consensus target price of $7.00, indicating a potential upside of 464.52%. Given Repare Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Repare Therapeutics is more favorable than NeuroSense Therapeutics.
In the previous week, Repare Therapeutics had 1 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 1 mentions for Repare Therapeutics and 0 mentions for NeuroSense Therapeutics. Repare Therapeutics' average media sentiment score of 0.32 beat NeuroSense Therapeutics' score of 0.00 indicating that Repare Therapeutics is being referred to more favorably in the news media.
Summary
Repare Therapeutics beats NeuroSense Therapeutics on 10 of the 17 factors compared between the two stocks.
Get NeuroSense Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
NeuroSense Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:NRSN) was last updated on 1/21/2025 by MarketBeat.com Staff